Table 2.
Thresholds | n (%) | Sensitivity, % (95% CI) | Specificity, % (95% CI) | PPV, % (95% CI) | NPV, % (95% CI) | Accuracy, % (95% CI) | AUC (95% CI) |
---|---|---|---|---|---|---|---|
All study participants, n = 1115 | |||||||
≥ 6 | 610 (55) | 94 (89–96) | 54 (51–57) | 31 (27–35) | 97 (96–99) | 61 (58–64) | 0.86 (0.83–0.88) |
≥ 7 | 499 (45) | 90 (84–93) | 65 (62–68) | 36 (32–40) | 97 (95–98) | 70 (67–72) | |
≥ 8 | 414 (37) | 87 (81–91) | 74 (71–77) | 42 (38–47) | 96 (95–98) | 76 (74–79) | |
≥ 9 | 336 (30) | 77 (71–83) | 80 (77–83) | 46 (41–52) | 94 (92–96) | 80 (77–82) | |
≥ 10 | 263 (24) | 64 (57–71) | 85 (83–88) | 49 (43–55) | 92 (89–93) | 81 (79–84) | |
With Metabolic syndrome only (WHO definition), n = 384 | |||||||
≥ 6 | 252 (66) | 97 (91–100) | 45 (39–51) | 37 (31–44) | 98 (93–100) | 58 (53–63) | 0.83 (0.79–0.87) |
≥ 7 | 215 (56) | 94 (86–98) | 57 (51–63) | 42 (36–49) | 96 (92–99) | 66 (61–71) | |
≥ 8 | 194 (51) | 94 (86–98) | 64 (58–70) | 47 (40–54) | 97 (93–99) | 72 (67–76) | |
≥ 9 | 161 (42) | 87 (78–93) | 73 (68–78) | 52 (44–60) | 94 (90–97) | 77 (72–81) | |
≥ 10 | 128 (33) | 69 (59–78) | 79 (73–83) | 52 (43–61) | 88 (84–92) | 88 (84–92) | |
Without Metabolic syndrome only (WHO definition), n = 731 | |||||||
≥ 6 | 358 (49) | 90 (83–95) | 58 (54–62) | 26 (22–31) | 97 (95–99) | 63 (59–66) | 0.86 (0.82–0.89) |
≥ 7 | 284 (39) | 86 (77–92) | 69 (65–72) | 31 (26–37) | 97 (94–98) | 71 (68–75) | |
≥ 8 | 220 (30) | 81 (72–88) | 78 (75–81) | 38 (32–45) | 96 (94–98) | 79 (75–82) | |
≥ 9 | 175 (24) | 68 (58–77) | 83 (80–86) | 41 (33–48) | 94 (92–96) | 81 (78–84) | |
≥ 10 | 135 (18) | 60 (50–69) | 88 (86–91) | 46 (37–55) | 93 (91–95) | 84 (81–87) |
PPV positive predictive value, NPV negative predictive value, AUC area under the receiver operating curve, CI confidence interval
Optimal thresholds in bold